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COPD Diagnostic Questionnaire (CDQ) for selecting at-risk patients for
spirometry: A cross-sectional study in Australian general practice
Abstract

Background: Using the COPD Diagnostic Questionnaire (CDQ) as a selection tool for spirometry could
potentially improve the efficiency and accuracy of chronic obstructive pulmonary disease (COPD) diagnosis
in at-risk patients. Aim: To identify an optimal single cut point for the CDQ that divides primary care patients
into low or high likelihood of COPD, with the latter group undergoing spirometry. Methods: Former or
current smokers aged 40-85 years with no prior COPD diagnosis were invited to a case-finding appointment
with the practice nurse at various general practices in Sydney, Australia. The CDQ was collected and pre- and
post-bronchodilator spirometry was performed. Cases with complete CDQ data and spirometry meeting
quality standards were analysed (1,054 out of 1,631 patients). CDQ cut points were selected from a receiver
operating characteristic (ROC) curve. Results: The area under the ROC curve was 0.713. A cut point of 19.5
had the optimal combination of sensitivity (63%) and specificity (70%) with two-thirds below this cut point.
A cut point of 14.5 corresponded to a sensitivity of 91%, specificity of 35% and negative predictive value of
96%, and 31% of patients below this cut point. Conclusions: The CDQ can be used to select patients at risk of
COPD for spirometry using one cut point. We consider two possible cut points. The 19.5 cut point excludes a
higher proportion of patients from undergoing spirometry with the trade-off of more false negatives. The 14.5
cut point has a high sensitivity and negative predictive value, includes more potential COPD cases but has a
higher rate of false positives. 2014 Primary Care Respiratory Society UK/Macmillan Publishers Limited.
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ARTICLE

OPEN

COPD Diagnostic Questionnaire (CDQ) for selecting at-risk
patients for spirometry: a cross-sectional study in Australian
general practice
Anthony J Stanley1, Iqbal Hasan2, Alan J Crockett3,4, Onno CP van Schayck5 and Nicholas A Zwar1
BACKGROUND: Using the COPD Diagnostic Questionnaire (CDQ) as a selection tool for spirometry could potentially improve the
efﬁciency and accuracy of chronic obstructive pulmonary disease (COPD) diagnosis in at-risk patients.
AIM: To identify an optimal single cut point for the CDQ that divides primary care patients into low or high likelihood of COPD, with
the latter group undergoing spirometry.
METHODS: Former or current smokers aged 40–85 years with no prior COPD diagnosis were invited to a case-ﬁnding appointment
with the practice nurse at various general practices in Sydney, Australia. The CDQ was collected and pre- and post-bronchodilator
spirometry was performed. Cases with complete CDQ data and spirometry meeting quality standards were analysed (1,054 out of
1,631 patients). CDQ cut points were selected from a receiver operating characteristic (ROC) curve.
RESULTS: The area under the ROC curve was 0.713. A cut point of 19.5 had the optimal combination of sensitivity (63%) and
speciﬁcity (70%) with two-thirds below this cut point. A cut point of 14.5 corresponded to a sensitivity of 91%, speciﬁcity of 35%
and negative predictive value of 96%, and 31% of patients below this cut point.
CONCLUSIONS: The CDQ can be used to select patients at risk of COPD for spirometry using one cut point. We consider two
possible cut points. The 19.5 cut point excludes a higher proportion of patients from undergoing spirometry with the trade-off of
more false negatives. The 14.5 cut point has a high sensitivity and negative predictive value, includes more potential COPD cases
but has a higher rate of false positives.
npj Primary Care Respiratory Medicine (2014) 24, 14024; doi:10.1038/npjpcrm.2014.24; published online 10 July 2014

INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterised by
airﬂow obstruction and is an important cause of mortality and
disability worldwide.1,2 COPD should be suspected in patients 40
years or older with symptoms such as dyspnoea, chronic cough
with or without sputum production and exposure to risk factors
such as tobacco smoke, smoke from home cooking or occupational dusts and chemicals.3 The gold standard for COPD diagnosis
is post-bronchodilator spirometry performed in those patients
suspected of having COPD.3
General practitioners have an important role in diagnosing
COPD as most patients with chronic or persistent respiratory
symptoms present in primary care.4 It is important to diagnose
COPD in those patients with risk factors to help relieve symptoms,
improve health status, prevent exacerbations and disease
progression, and reduce early mortality.3 It is also important to
avoid misdiagnosis of COPD to limit inappropriate use of COPD
medications leading to unnecessary health-care expenditure and
potential adverse effects.5 There are barriers to spirometry use in
general practice, which include lack of expertise in performing
spirometry, poor access to a well-maintained spirometer and
the time-consuming nature of pre- and post-bronchodilator
spirometry.6,7 This can lead to under-diagnosis and misdiagnosis

of COPD, particularly if general practitioners rely on a symptombased assessment for the diagnosis.5,6
The COPD Diagnostic Questionnaire (CDQ) is an 8-item tool
designed by the COPD Questionnaire Study Group from a crosssectional study of primary care patients ⩾ 40 years old from the
United Kingdom and the United States with a history of smoking
but no prior respiratory diagnosis (Table 1).8,9 It was developed to
improve the efﬁciency and accuracy of COPD diagnosis in primary
care by removing the need for spirometry in low-risk patients.9
Although not initially designed to be a diagnostic tool, it has been
externally validated in various international studies,10–13 as well as
a previous study by our group in an Australian general practice
cohort.14 These studies showed that the CDQ does not perform
well as a COPD diagnostic tool. However, it could be used as a
ﬁltering tool to select patients at high risk of COPD to undergo
spirometry.9,15
The CDQ in its original format has a three-tier scoring system
with two cut points (16.5 and 19.5) that divide subjects into three
groups of COPD likelihood; low (o 16.5), medium (16.5–19.5) and
high (419.5).9 Price et al.9 proposed that the high likelihood
group should, and the low likelihood group should not, require
spirometry in most regions. Furthermore, Price et al.9 suggested
that the intermediate zone could undergo spirometry but where
there were limited resources to do spirometry, these patients

1
School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Kensington, New South Wales, Australia; 2Centre for Health Equity
Training Research and Evaluation (CHETRE), Ingham Institute, Liverpool BC, New South Wales, Australia; 3School of Health, University of South Australia, Adelaide, South Australia,
Australia; 4Discipline of General Practice, School of Population Health, University of Adelaide, Adelaide, South Australia, Australia and 5Department of General Practice, CAHPRI
School for Public Health and Care, Maastricht University Medical Centre, Maastricht, The Netherlands.
Correspondence: AJ Stanley (ajstanley8@gmail.com)
Received 30 January 2014; revised 31 March 2014; accepted 6 May 2014

© 2014 Primary Care Respiratory Society UK/Macmillan Publishers Limited

CDQ for selecting at-risk patients for spirometry
AJ Stanley et al

2
Table 1.

COPD Diagnostic Questionnaire (CDQ)

Question
What is your age in years?

What is the total number of years you have smoked?
How many cigarettes do you currently smoke each day?
(If you are an ex-smoker, how many did you smoke each day?)
Packs per day = cigarettes per day/20 cigarettes per pack
Pack-years = packs per day × years smoked
What is your weight in kilograms?
What is your height in metres?
Body mass index (BMI) = weight (kg)/(height (m))2
Does the weather affect your cough?
Do you ever cough up phlegm (sputum) from your chest when you don’t have a cold?
Do you usually cough up phlegm (sputum) from your chest ﬁrst thing in the morning?
How frequently do you wheeze?
Do you have or have you had any allergies?

could be followed up clinically and spirometry deferred to a later
date to minimise the number of unnecessary spirometries.
The International Primary Care Respiratory Group recommended a diagnostic process where all patients over 35 years
old should be evaluated for their risk of having COPD by
completing the CDQ, with any score above the 16.5 cut point
going on to have diagnostic spirometry.15 This recognises from a
clinical point of view that a single cut point is needed to decide
whether to proceed to spirometry. However, there is a lack of
evidence to show the 16.5 cut point is optimal for this ﬁltering
process. The sensitivities at the 16.5 cut point from four CDQ
external validation studies were 89–94%.10–13 The aim of this
study was ﬁnd an optimal single cut point that divides primary
care patients into a low or high likelihood of COPD, with the high
likelihood patient scoring above the cut point progressing to
spirometry. We aim to set an optimal CDQ cut point that
maximises sensitivity while excluding subjects at low risk of COPD,
therefore reducing the number of spirometries performed.
MATERIALS AND METHODS
Subject recruitment for this study

Response categories

CDQ score

40–49 years old
50–59
60–69
70+
0–14 pack-years
15–24
25–49
50+

0
4
8
10
0
2
3
7

BMIo 25.4
25.4–29.7
o29.7
Yes
No/No cough
Yes
No
Yes
No
Occasionally or more often
Never
Yes
No

5
1
0
3
0
3
0
0
3
4
0
0
3

CDQ score and statistical analysis
The analysis methods were based on a protocol outlined by Price et al.9
with the CDQ having a range of scores 0–38. The sensitivity, speciﬁcity,
positive predictive value and negative predicative value were calculated at
1-point intervals between the minimum and maximum scores using the
non-parametric method when determining the receiver operating
characteristic (ROC) area under the curve (ROCAUC). These intervals were
used to determine cut points. The raw CDQ score was used as the
screening test variable and the COPD diagnosis from spirometry as the
dichotomised classiﬁcation variable for calculation of the ROCAUC. Analyses
were performed using SPSS (IBM, Armonk, NY, USA) and Microsoft Excel
(Microsoft, Redmond, WA, USA) software.

RESULTS
Characteristics of participants
As reported in our earlier publication, there were 1,631 patients
who attended for case-ﬁnding recruitment. Of these, 1,054 (65%)
had complete CDQ recorded and spirometry meeting quality
criteria for analysis.14 There were 178 patients (10.9% of 1,631)
who were excluded due to incomplete CDQs and 472 (28.9%) had
spirometry not meeting quality criteria. There were 63 patients
(3.9%) who had both incomplete CDQ and spirometry not
meeting quality criteria. Table 2 shows the population characteristics of the group. After post-bronchodilator spirometry, 13.1% of
the total population were diagnosed with COPD. The group
scoring 419.5 had a third of all patients and about two-thirds of
all COPD patients but 20% of patients with COPD scored o 16.5.

Methods were outlined in detail in our previous CDQ validation study on
the same patient cohort.14 In brief, patients in this study were from a caseﬁnding recruitment group for a cluster-randomised controlled trial of early
intervention in COPD by practice nurse (PN)–general practitioner
teams.14,16 Patients were 40–85-year-old former or current smokers with
no previous diagnosis of COPD from general practices in Sydney. They
completed the CDQ with the PN followed by the PN performing pre- and
post-bronchodilator spirometry based on the American Thoracic Society
and the European Respiratory Society (ATS/ERS) 2005 lung function
guidelines.17,18 The PNs used the practice’s own spirometer, which had
been calibrated by the research team. Spirometry tracings were
independently reviewed by a respiratory physiologist (AJC). Cases where
spirometry met quality standards based on ATS/ERS 2005 criteria
and complete CDQ data were present were included for the analysis.16
A study diagnosis of COPD based on Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines was assigned to subjects
who had a post-bronchodilator forced expiratory volume in 1 s (FEV1)/
forced vital capacity ratio of o 0.7.3 The criteria for COPD severity
grading was based on the GOLD staging criteria: Stage I—FEV1 ⩾ 80%
(mild), Stage II—50% ⩽ FEV1 o80% (moderate), Stage III—30% ⩽
FEV1 o50% (severe) and Stage IV—FEV1 o30% (very severe).3

CDQ performance to identify COPD at different cut points
Figure 1 shows the ROC curve and the position of the original two
cut points. The ROCAUC was 0.713 ± 0.023 with the higher cut point
closer to the middle of the curve. Table 3 shows the sensitivity,
speciﬁcity, predictive values and proportion of patients below
various select cut points after ROC curve analysis. The sensitivity
and speciﬁcity for the 16.5 cut point were 79.7 and 46.8%,
respectively. The sensitivity and speciﬁcity for the 19.5 cut point
were 63.0 and 70.1%, respectively. About two-thirds of patients
scored below the 19.5 cut point and about 43% scored below the
16.5 cut point. The lowest cut point with at least 90% sensitivity
was 14.5. This corresponded to a speciﬁcity of about 35%, positive
predictive value of 17%, negative predicative value of 96% and a
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Table 2.

Table 3.

Population characteristics of the study group
Study group

Patients (n)
Age (years)
Male number (%)
Body mass index (kg/m2)
Smoking history (pack-years)
Proportion with COPDa (%)

1054
61.0 ± 11.3
546 (51.8)
28.1 ± 5.3
24.1 ± 23.7
13.1

Pulmonary function, % of predicted
Post-bronchodilator (BD) FEV1
Post-BD FVC
Average post-BD FEV1/FVC %

94.5 ± 18.3
95.9 ± 16.5
77.5 ± 8.1

Pulmonary function (L)
Post-BD FEV1
Post-BD FVC
CDQ score

2.8 ± 0.8
3.6 ± 1.0
17.2 ± 5.5

Distribution in CDQ groups (% of 1,054)
CDQo16.5
CDQ 16.5–19.5
CDQ419.5

43.4
22.4
34.3

COPD patients in CDQ groups (% of 138)
CDQ o16.5
CDQ 16.5–19.5
CDQ 419.5

20.3
16.7
63.0

Performance of CDQ at different cut points

Cut point Sensitivity Speciﬁcity

9.5
10.5
11.5
12.5
13.5
14.5
15.5
16.5
17.5
18.5
19.5
20.5
21.5
22.5
23.5
24.5

0.978
0.964
0.964
0.935
0.928
0.906
0.833
0.797
0.768
0.674
0.630
0.572
0.471
0.355
0.297
0.196

Positive
predictive
value (%)

Negative
predictive
value (%)

Patients
below the
cut point
(%)

14.1
14.3
15.2
15.4
16.2
17.3
17.6
18.4
20.5
22.2
24.1
25.1
28.6
28.2
29.4
28.8

96.8
95.9
97.2
95.9
96.2
96.1
94.2
93.9
94.0
92.9
92.6
92.0
91.2
89.9
89.4
88.4

8.9
11.4
17.0
20.7
25.1
31.3
38.0
43.4
51.0
60.2
65.7
70.2
78.5
83.5
86.8
91.1

0.099
0.126
0.190
0.228
0.278
0.346
0.412
0.468
0.552
0.644
0.701
0.743
0.823
0.864
0.893
0.927

Abbreviation: CDQ, COPD Diagnostic Questionnaire.

Data are presented as mean ± s.d. unless indicated otherwise.
Abbreviations: CDQ, COPD Diagnostic Questionnaire; COPD, chronic
obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s;
FVC, forced vital capacity.
a
Deﬁned by post-BD FEV1/FVC o0.70 as per Global Initiative for Chronic
Obstructive Lung Disease criteria.3

Table 4. GOLD stage distribution of COPD-positive patients by
original CDQ cut points and the 14.5 cut point
All
GOLD I
62
GOLD II
66
GOLD III
10
Total patients 138

o 14.5 414.5 o 16.5 416.5 o19.5 419.5
10
3
0
13

52
63
10
125

19
8
1
28

43
58
9
110

30
19
2
51

32
47
8
87

COPD GOLD staging classiﬁcation.3 Stage I—FEV1 ⩾ 80%; Stage II—50%
⩽ FEV1 o 80%; Stage III—30% ⩽ FEV1 o50%; Stage IV—FEV1 o 30%.
Abbreviations: CDQ, COPD Diagnostic Questionnaire; COPD, chronic
obstructive pulmonary disease; GOLD, Global Initiative for Chronic
Obstructive Lung Disease.

1.0

Sensitivity

0.8

corresponded to the 23.5 cut point, with sensitivity of about 30%,
speciﬁcity of 90% and 87% of patients scoring below the cut point.

0.6

0.4

0.2
Area under the ROC curve (ROCAUC) = 0.713±0.023

0.0
0.0

0.2

0.4
0.6
1–Specificity

0.8

1.0

Figure 1. Receiver operating characteristic (ROC) curve comparing
the COPD Diagnostic Questionnaire score to chronic obstructive
pulmonary disease diagnosis. Cut point 16.5—grey star; 19.5—black
star. An ROCAUC of 0.5 is indicated by the solid diagonal line.

GOLD severity grading versus CDQ score
Table 4 shows the distribution of patients with COPD by GOLD
staging in the entire group and those groups separated by the
14.5 and 19.5 cut points. No one had GOLD stage IV COPD. The
majority of patients had GOLD stage II (66 (47.8%)). About 37% of
COPD-positive patients fell below the 19.5 cut point that includes
2 out of 10 patients (20%) with GOLD stage III and 19 of 66 (28.8%)
with GOLD stage II. There were 10% of GOLD stage III COPD
patients who scored below the 16.5 cut point, with 68% of
patients below this cut point being GOLD stage I. With a 14.5 cut
point, 10 of 13 COPD-positive patients below the cut point were in
GOLD stage I with the other 3 in GOLD stage II.

proportion below the cut point of 31%. A sensitivity of at least
95% corresponded to a cut point of 11.5, with sensitivity of 96.4%,
speciﬁcity of about 19%, positive predictive value of 15%, negative
predicative value of 97% and a proportion below the cut point of
about 17%. The maximal positive predictive value of 29.4%

DISCUSSION
Main ﬁndings
Although recommended in guidelines, performing spirometry on
all current and former smokers has proved difﬁcult to implement
in primary care.3,9 In this paper we examined the role of the CDQ
as a ﬁltering tool, where a single cut point was chosen to identify
patients at higher risk of having COPD and needing to progress to
diagnostic spirometry. The authors felt this was a simpler

© 2014 Primary Care Respiratory Society UK/Macmillan Publishers Limited
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spirometry referral model than the original two cut point model
proposed by Price et al.,9 removing the uncertainty of having an
intermediate likelihood group that may or may not undergo
spirometry.
The literature suggests that a cut point with the best balance
between sensitivity and speciﬁcity based on the ROC curve is
considered best at discriminating between diseased and nondiseased cases.19,20 In this study, using these methods would
result in 19.5 being the optimal cut point. However, this has a
sensitivity of only 63% and 37% of COPD diagnoses would be
missed. To some clinicians, this would be considered an
unacceptably high rate of missed COPD diagnoses. This is
compared with 9.4% of potential COPD diagnoses excluded by
the 14.5 cut point for example. If the 16.5 and 19.5 cut points
originally proposed for the CDQ were applied to the study
population, sensitivity and negative predictive values would be
less than the 14.5 cut point.
Inﬂuences on choosing an optimal cut point are the need to
maximise the detection of COPD while making a substantial
reduction in the burden of performing spirometry. A highly
sensitive cut point would suit this objective better than one with a
high speciﬁty.21 It is difﬁcult to ﬁnd evidence supporting an ideal
threshold sensitivity level; however, selection of an optimal cut
point can be varied to increase sensitivity or speciﬁcity depending
on what the test is used for.20 The authors proposed a potential
cut point of 14.5 because of its high sensitivity similar to the 16.5
cut point in other studies (90.6%) and high negative predictive
value (96%).10–13 At the same time, 31% of patients in the low
likelihood group do not need to undergo spirometry. The authors
felt that a single cut point o 14.5 would lead to a minimal gain in
sensitivity while resulting in a substantial increase in spirometries
performed. For example, choosing a 12.5 cut point would lead to a
~ 3% increase in sensitivity but would require 10% more
spirometries than a 14.5 cut point (21 vs 31% patients below
cut point).
On the basis of the GOLD COPD severity criteria, the majority of
COPD patients were in GOLD stage II (66 (47.8%)) with most
patients below the 16.5 and 19.5 cut points being in GOLD stage I
(Table 4).3 By using a 14.5 cut point for spirometry selection, no
GOLD stage III COPD patients would miss out on spirometry,
whereas 2 out of 10 patients (20%) with GOLD stage III score
below the 19.5 cut point would miss. Clinicians concerned about
potentially missing patients with severe COPD would perhaps
prefer a more sensitive cut point.
Strengths and limitations of this study
One strength of this study is that there was a large sample of
primary care patients from a different population (Australia) to the
original CDQ study (USA and UK) made up of former and current
smokers, unlike the ﬁrst CDQ validation study in the Netherlands
where all patients were current smokers.9,10 This study was
undertaken across several sites using each practice’s nurses and
pre-existing spirometry machines. This represents real world use
of spirometry in Australian general practice rather than laboratorybased methods, despite 35% of patients being excluded from the
statistical analysis due to incomplete CDQ or spirometry not
meeting quality criteria.
Asymptomatic patients will generally score lower on the CDQ
than symptomatic patients (Table 1). As our sample included
patients without respiratory symptoms, this may underestimate
the ability of the CDQ to detect cases of COPD as deﬁned by the
GOLD guidelines.3 This limitation also applies to other CDQ studies
that looked at detecting spirometrically deﬁned COPD in patients
with risk factors for COPD but not necessarily with symptoms.9–14
npj Primary Care Respiratory Medicine (2014) 14024

Interpretation of ﬁndings in relation to previously published work
There is variation in performance of CDQ across populations and
therefore the value of a single cut point varies.11 Several studies
have examined the sensitivities and speciﬁcities of the CDQ at the
16.5 and 19.5 cut points. Sensitivities of 89–94% at the lower cut
point and 66–85% at the higher cut point were found for four CDQ
external validation studies.10–13 Sensitivities at the 16.5 cut point
in the validation studies by Frith et al. and Sichletidis et al., for
example, were 91%. This sensitivity is equivalent to the 14.5 cut
point in this study.12,13 However, the original CDQ study and this
study had a sensitivity of ~ 80% at the 16.5 cut point.9 These
ﬁndings suggest that the optimal cut point will vary between
populations. For a particular region, a cut point that has the
optimal combination of sensitivity or speciﬁcity or whose
sensitivity is ⩾ 90% could be chosen based on the study with a
similar population.
Another approach to ﬁltering patients for diagnostic spirometry
is to use the Piko-6 ﬂow meter (nSpire Health, Longmont, CO,
USA).12,13 Sichletidis et al.12 proposed combining CDQ and postbronchodilator Piko-6 ﬂow meter to ‘screen’ patients for
spirometry. Frith et al.13 decided to use pre-bronchodilator Piko6 on its own as a selection tool for spirometry rather than
combining it with the CDQ. This appears to be a simpler approach
than the Sichletidis et al. model, particularly with no bronchodilation needed for the Piko-6 meter.12,13 Frith et al. selected an
optimal cut point for the Piko-6 FEV1/FEV6 ratio based on the
optimal combination of sensitivity and speciﬁcity, even though
sensitivity for FEV1/FEV6 o 0.75 was 81% compared to 93% for
FEV1/FEV6 o 0.8.13 They postulated using the Piko-6 meter as a
selection tool for spirometry with the o0.75 cut point although
the o 0.8 cut point would lead to a smaller number of potential
COPD diagnoses being excluded.13
An editorial by Kotz and van Schayck21 compared the
performance of the CDQ to the Piko-6 ﬂow meter from the Frith
et al.13 and Sichletidis et al.12 studies. They wrote that the number
of avoidable (negative) spirometries was much lower when using
the Piko-6 but twice as many patients with COPD would be missed
compared with the CDQ.19 An advantage of the CDQ is that it can
be used without medical assistance, unlike the Piko-6.19 This
means the Piko-6 could require longer training time than the CDQ
and be more difﬁcult for the patient to perform.
Implications for future research, policy and practice
Using the CDQ as a ﬁlter to select patients for diagnostic
spirometry could potentially reduce the burden of spirometry in
primary care with less clinical staff time needed. This could prove
to be a cost-effective strategy for diagnosing COPD. Evaluating the
implementation of the CDQ as a spirometry-ﬁltering tool in
primary care would be needed, particularly looking at the cost of
time taken to administer the CDQ and the training time involved
in educating PNs and general practitioners on its use.
Deciding on the optimal CDQ cut point for a particular region
should be based on the results from one of the six CDQ
studies.9–14 Consensus guidelines regarding which cut point is
optimal for which population would make the clinician’s job
easier. Furthermore, establishing a protocol on how to follow-up
patients in the low likelihood group is also important, such as how
often to repeat the CDQ, e.g., comparing six monthly with
annual CDQs.
Conclusions
The results of this CDQ study suggest that the questionnaire can
be used effectively as a selection tool for patients at high risk of
COPD to undergo further spirometry by excluding subjects at low
risk of COPD. This will limit the number of spirometries performed
and exclude a small number of potential positive COPD diagnoses
© 2014 Primary Care Respiratory Society UK/Macmillan Publishers Limited
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by setting a single cut point for the CDQ. We suggest
consideration of two possible cut points. A single cut point of
19.5 based on ROC curve criteria can be considered to be an ideal
cut point as it has the best balance of sensitivity and speciﬁcity.
However, this has a substantial false-negative rate compared with
a lower cut point of 14.5, and the 19.5 cut point potentially
excludes a small number of patients with severe COPD. The 14.5
cut point increases sensitivity and negative predictive value while
reducing false-negative CDQs. However, this cut point excludes a
smaller proportion of patients from undergoing spirometry. The
single cut point concept can be applied to different populations
using our study’s protocol. The pros and cons of this approach and
the proposed cut points warrant debate in the primary care
respiratory community.
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